Anogenital warts are the most frequently sexually transmitted disease caused by viral infections worldwide. People's lifetime risk to suffer from this disease or HPV-associated precancers counts to more than 10%. The therapy and the recurrence rates of both disorders continue to be challenging in Germany because the coverage rate of the preventive HPV vaccination is still insufficient. This underlines the importance of a recently passed interdisciplinary German guideline on anogenital HPV lesions. This article summarizes the main aspects of the new guideline. Specialists should be consulted by children, pregnant women, individuals suffering from immunodeficiency and people frequently having relapses of HPV-associated diseases or having lesions being accessible only endoscopically.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00120-018-0580-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anal cancer prevention: A field in need of scientific Advancement.
Virology
January 2025
Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; Department of Surgery, William S. Middleton Memorial Veteran's Hospital, Madison, WI, USA.
Despite the availability of several human papillomavirus (HPV) vaccines, the incidence of HPV-associated anal cancer is growing at a rate of 2.2% each year. As shown in results from the recent Phase III ANCHOR study, the treatment of high-grade anal lesions in people living with HIV (PLWH) can significantly reduce rates of anal cancer development compared to active surveillance alone.
View Article and Find Full Text PDFHuman papillomavirus-associated cancers, precancers, and genital warts in Denmark, 2000-2022 - Current burden of disease and population impact of multi-cohort HPV vaccination.
Prev Med
December 2024
Unit of Virus, Lifestyle and Genes, Danish Cancer Institute, Strandboulevarden 49, 2100 Copenhagen O, Denmark; Department of Clinical Medicine, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen N, Denmark; Department of Gynecology, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen O, Denmark. Electronic address:
Article Synopsis
- The study analyzed cancer trends related to human papillomavirus (HPV) in Denmark from 2000 to 2022, focusing on cervical precancer, genital warts, and overall disease burden post-HPV vaccination.
- Findings revealed a significant decline in age-standardized incidence rates (ASRs) for cervical precancer and genital warts, particularly among women, while HPV-associated cancers have been rising in men and non-cervical sites among women.
- The conclusion emphasized that, even with vaccination efforts leading to decreased cases of certain HPV-related conditions, HPV-associated diseases continue to pose a public health challenge, especially among men.
Phase I study on the pharmacokinetics of intravaginal, self-administered artesunate vaginal pessaries among women in Kenya.
medRxiv
August 2024
Department of Obstetrics and Gynecology, Maseno University School of Medicine, P.O, Kisumu, Kenya.
Unlabelled: Cervical cancer remains a significant global health issue, especially in low- and middle-income countries (LMICs), where access to prevention and treatment is limited and women are at a higher risk of cervical cancer. Artesunate, a widely available drug used to treat malaria, has shown promise in treating human papillomavirus (HPV)-associated anogenital lesions including high-grade cervical precancer, in a recent Phase I studies in the United States. Data on the pharmacokinetics of artesunate following intravaginal use, and its implications on malaria resistance, are lacking.
View Article and Find Full Text PDFMonitoring mouse papillomavirus-associated cancer development using longitudinal Pap smear screening.
mBio
August 2024
The Jake Gittlen Laboratories for Cancer Research, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA.
Unlabelled: A substantial percentage of the population remains at risk for cervical cancer due to pre-existing human papillomavirus (HPV) infections, despite prophylactic vaccines. Early diagnosis and treatment are crucial for better disease outcomes. The development of new treatments heavily relies on suitable preclinical model systems.
View Article and Find Full Text PDFTirbanibulin decreases cell proliferation and downregulates protein expression of oncogenic pathways in human papillomavirus containing HeLa cells.
Arch Dermatol Res
July 2024
Department of Dermatology, The University of Texas McGovern Medical School, Houston, TX, USA.
Article Synopsis
- - Tirbanibulin 1% ointment, approved by the EU in 2021, is used to treat actinic keratoses and has shown effectiveness against various HPV-related lesions and cancers.
- - A study on HeLa cells treated with tirbanibulin revealed that it inhibits cell proliferation with an IC of 31.49 nmol/L, downregulating multiple key proteins involved in cancer progression and cell cycle regulation.
- - The findings suggest that tirbanibulin affects HPV oncoprotein expression and activates apoptotic pathways, indicating a potential mechanism for its antiproliferative effects.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!